175 related articles for article (PubMed ID: 35197127)
1. Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients.
Tahiru W; Izarra Santamaria A; Hultdin J; Wu WY; Späth F
Exp Hematol Oncol; 2022 Feb; 11(1):8. PubMed ID: 35197127
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
3. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal gammopathy of undetermined significance and evolution to myeloma: Experience in 153 patients].
López Gómez JM; Sacristán Enciso B; Fernández-Cavada Pollo MJ; Bueno García V; Gómez Vera S
Semergen; 2021 Oct; 47(7):441-447. PubMed ID: 34479794
[TBL] [Abstract][Full Text] [Related]
5. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
6. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
[TBL] [Abstract][Full Text] [Related]
7. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Landgren O; Hofmann JN; McShane CM; Santo L; Hultcrantz M; Korde N; Mailankody S; Kazandjian D; Murata K; Thoren K; Ramanathan L; Dogan A; Rustad E; Lu SX; Akhlaghi T; Kristinsson SY; Björkholm M; Devlin S; Purdue MP; Pfeiffer RM; Turesson I
JAMA Oncol; 2019 Sep; 5(9):1293-1301. PubMed ID: 31318385
[TBL] [Abstract][Full Text] [Related]
8. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients.
Steiner N; Göbel G; Suchecki P; Prokop W; Neuwirt H; Gunsilius E
Oncotarget; 2018 Jan; 9(2):2344-2356. PubMed ID: 29416776
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma.
Gran C; Liwing J; Wagner AK; Verhoek A; Gezin A; Alici E; Nahi H
Am J Hematol; 2021 Jan; 96(1):23-30. PubMed ID: 32936979
[TBL] [Abstract][Full Text] [Related]
13. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
Spira D; Weisel K; Brodoefel H; Schulze M; Kaufmann S; Horger M
Acad Radiol; 2012 Jan; 19(1):89-94. PubMed ID: 22142681
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Cerhan JR; Rajkumar SV
N Engl J Med; 2018 Jan; 378(3):241-249. PubMed ID: 29342381
[TBL] [Abstract][Full Text] [Related]
16. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
[TBL] [Abstract][Full Text] [Related]
17. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.
Bianchi G; Kyle RA; Colby CL; Larson DR; Kumar S; Katzmann JA; Dispenzieri A; Therneau TM; Cerhan JR; Melton LJ; Rajkumar SV
Blood; 2010 Sep; 116(12):2019-25; quiz 2197. PubMed ID: 20495076
[TBL] [Abstract][Full Text] [Related]
18. A gene signature can predict risk of MGUS progressing to multiple myeloma.
Sun F; Cheng Y; Ying J; Mery D; Al Hadidi S; Wanchai V; Siegel ER; Xu H; Gai D; Ashby TC; Bailey C; Chen JR; Schinke C; Thanendrarajan S; Zangari M; Janz S; Barlogie B; Van Rhee F; Tricot G; Shaughnessy JD; Zhan F
J Hematol Oncol; 2023 Jun; 16(1):70. PubMed ID: 37386588
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
[TBL] [Abstract][Full Text] [Related]
20. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Kyle RA; Rajkumar SV
Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
